Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:082800)

Vivozon Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	3,820	6,525	7,987	2,351	13,799	64,331
Short-Term Investments	2,351	2,211	5,330	11,600	14,880	129.95
Trading Asset Securities	1,252	1,252	4,404	12,448	35,376	26,216
Cash & Short-Term Investments	7,423	9,988	17,721	26,400	64,055	90,677
Cash Growth	-27.98%	-43.64%	-32.88%	-58.79%	-29.36%	32.66%
Accounts Receivable	-	-	-	8,847	10,712	10,746
Other Receivables	-	-	-	347.19	2,428	652.92
Receivables	-	-	-	9,694	13,163	11,509
Inventory	19,079	19,637	12,994	11,199	16,034	12,927
Prepaid Expenses	-	-	-	20.8	421.39	47.34
Other Current Assets	9,267	14,782	14,423	248.44	2,659	3,155
Total Current Assets	35,769	44,407	45,138	47,562	96,333	118,315
Property, Plant & Equipment	31,409	31,814	25,521	33,968	32,807	25,228
Long-Term Investments	92,327	94,560	91,484	95,242	45,857	48,493
Goodwill	-	-	-	-	-	19,341
Other Intangible Assets	3,937	4,190	4,631	5,574	8,612	26,158
Long-Term Deferred Tax Assets	-	-	-	-	3,431	2,372
Long-Term Deferred Charges	9,117	7,864	6,209	3,437	2,880	1,267
Other Long-Term Assets	2,764	1,614	662.93	1,006	653.97	4,866
Total Assets	175,323	184,449	173,647	187,074	194,471	248,159
Accounts Payable	-	11,827	10,632	6,152	6,622	6,332
Accrued Expenses	-	1,575	1,532	1,848	2,167	1,843
Short-Term Debt	37,871	34,476	39,996	52,572	67,993	90,952
Current Portion of Long-Term Debt	-	-	-	5,604	867.11	867.13
Current Portion of Leases	1,134	1,182	624.62	653.17	610.93	625.91
Current Income Taxes Payable	-	30.1	-	-	-	-
Current Unearned Revenue	-	1,906	3,504	3,685	3,685	3,685
Other Current Liabilities	31,243	21,215	8,490	8,746	7,078	7,265
Total Current Liabilities	70,248	72,211	64,779	79,261	89,023	111,570
Long-Term Debt	-	-	-	-	13,958	14,871
Long-Term Leases	435.34	841.95	994.18	1,481	685.36	1,107
Long-Term Deferred Tax Liabilities	923.51	923.51	923.51	927.93	1,823	5,596
Other Long-Term Liabilities	182.32	238.67	283.74	130.07	150.4	304.9
Total Liabilities	76,141	78,022	69,580	83,609	107,928	136,600
Common Stock	125,262	125,262	120,529	117,022	84,953	70,326
Additional Paid-In Capital	250,604	249,419	245,296	243,684	216,611	184,994
Retained Earnings	-279,825	-271,829	-261,313	-257,365	-216,914	-147,709
Treasury Stock	-10.05	-13.12	-18.19	-	-	-
Comprehensive Income & Other	3,151	3,588	-427.4	125.39	469.82	192.97
Total Common Equity	99,181	106,427	104,067	103,466	85,120	107,803
Minority Interest	-	-	-	-	1,422	3,757
Shareholders' Equity	99,181	106,427	104,067	103,466	86,542	111,560
Total Liabilities & Equity	175,323	184,449	173,647	187,074	194,471	248,159
Total Debt	39,440	36,500	41,615	60,310	84,115	108,424
Net Cash (Debt)	-32,018	-26,512	-23,894	-33,910	-20,060	-17,747
Net Cash Per Share	-656.60	-555.26	-500.74	-779.45	-615.13	-677.62
Filing Date Shares Outstanding	49.55	49.38	47.21	46.81	33.98	28.13
Total Common Shares Outstanding	49.55	49.38	47.21	46.81	33.98	28.13
Working Capital	-34,479	-27,804	-19,640	-31,699	7,310	6,745
Book Value Per Share	2001.66	2155.28	2204.51	2210.40	2504.91	3832.28
Tangible Book Value	95,244	102,237	99,436	97,892	76,508	62,304
Tangible Book Value Per Share	1922.21	2070.44	2106.41	2091.33	2251.47	2214.83
Land	6,037	6,037	6,037	6,037	6,183	6,183
Buildings	6,998	6,835	6,678	6,557	7,886	8,487
Machinery	12,787	23,153	23,401	20,015	22,216	23,749
Construction In Progress	4,044	7,598	1,943	12,132	9,142	83.06

Source: S&P Global Market Intelligence. Standard template. Financial Sources.